Overview


According to FutureWise analysis the market for anti-venom in 2023 is US$ 0.65 billion, and is expected to reach US$ 1.32 billion by 2031 at a CAGR of 9.1%.

Anti-venom, also called antivenin, is an antibody therapy that disables the toxins within a specific venom if injected quickly into a patient after a venoums bite. Anti-venoms are purified antibodies targeting venoms or venom components. These antibodies are derived from animals that have been exposed to injected venoms. Venom is sourced from various animals in different ways.  Snakes and funnel web spiders, for instance, undergo a milking process to extract their venom. Stonefish, redback spiders, and box jellyfish, on the other hand, have their anti-venoms made through dissection to obtain the venom. This may be a hazardous process. Small doses of venom or its components are injected into the creature, and the dose gradually increases as the animal builds up a tolerance to the venom.

Anti-venoms are classified into two types: monovalent and polyvalent anti-venom. Monovalent anti-venoms have a lower volume of specific antibodies that may reduce reactions but require accurate snake identification to be used. Monovalent anti-venoms are produced via the immunization of large animals, e.g., horses, with one venom, after which the horse serum can neutralize the homologous venom with minimal or no cross-neutralization against other venoms. Polyvalent anti-venoms are larger in volume and may have a higher reaction rate. They are produced via immunization with several snake venoms, and the serum can neutralize all the venoms used in its production.

FutureWise Market Research has published a report that provides an insightful analysis anti-venom market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, anti-venom market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Medtoxin Venom Laboratories
  • Institute of Immunology
  • Alomone Labs, Ltd.
  • Sigma Aldrich
  • Wyeth Pharmaceuticals Limited
  • Protherics PLC
  • Bharat Serums and Vaccines Limited
  • Butantan Institute
  • Haffkine Bio-Pharmaceutical Corporation Limited
  • Micropaharm Limited

(Note: The list of the major players will be updated with the latest market scenario and trends)
 

Recent Developments in Anti-Venom Market:

  • In August 2022, The IISC (Indian Institute of Science) Labs, in collaboration with Bharat Serums and Vaccines (BSV), an Indian pharmaceutical firm, has been working towards the development of advanced treatments, including anti-venom, for snake bites.
  • In July 2022, the cornerstone for the Anti-venom Research and Development Centre (AVRDC) was laid at the IBAB (Institute of Bioinformatics and Applied Biotechnology), Bengaluru Helix Biotech Park, Electronics City, to increase the production activities for anti-venom.

The increasing prevalence of venomous snakes and rising incidence of snakebite cases are expected to increase demand for the anti-venom market. As human populations expand into habitats shared with venomous reptiles, encounters, and bites are rising. Urbanization, agricultural expansion, and climate change are some of the factors contributing to these anti-venom incidences. Additionally, enhanced reporting and diagnostic abilities in healthcare systems shed light on the extent of snakebite incidents, further driving the critical need for accessible and effective anti-venom treatments. Moreover, research and technological progress in the field of toxicology holds immense promise for the advancement of anti-venom products. Ongoing research efforts are unveiling deeper insights into the complex composition of snake venoms and the detailed mechanisms by which they affect the human body. Furthermore, advanced technologies, such as genetic engineering and advanced purification processes, allow researchers to create anti-venoms with enhanced efficiency, decreased side effects, and improved stability. Therefore, harnessing these innovations and developing next-generation anti-venom therapies is poised to modernize the treatment landscape for snakebite victims, offering a higher chance of survival and recovery, further propelling the target market over the forecast period. However, the high production cost of anti-venom significantly hinders the financial conditions, mainly originating from the complex processes of venom extraction, purification, and rigorous testing. Extracting venom from venomous animals demands skilled personnel, specialized facilities, and safety measures, all of which require substantial costs. Also, the vast testing procedures, including in vitro and in vivo experiments, clinical trials, and regulatory adherence, necessitate substantial financial investments. Henceforth, these factors are anticipated to restrain the market growth over the projection period.

By Type

  • Monovalent Antivenom
  • Polyvalent Antivenom

By Reptile

  • Snake
    • Common Cobra
    • Common Krait
    • Russell Viper
    • Others
  • Scorpion
  • Spider
  • Others

By Mode Of Action

  • Cytotoxic
  • Neurotoxic
  • Haemotoxic
  • Cardiotoxic
  • Myotoxic
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to the factors including the increasing incidence of snake bites, the thriving travel and tourism sector, implementation of numerous government initiatives to combat snake bites, such as education and training programs, product launches, and intensive investments in research and development (R&D) activities of new anti-venom products are contributing to the market growth. For instance, in June 2021, the CDC reported that approximately 7,000–8,000 individuals are bitten by venomous snakes in the United States, and about five of among those individuals die. Workers are more likely to suffer lasting injuries from snake bites than the likelihood of fatalities. In addition, with the rising demand for animal-based protein, there is an increase in the number of livestock and other animals at risk of snake bites, which further presents growth opportunities for the market in the region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Anti-Venom Market By Type, By Reptile, By Mode Of Action and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Anti-Venom Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anti-Venom Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Anti-Venom Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Anti-Venom Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Monovalent Antivenom
        2. Polyvalent Antivenom

  • 8.   Anti-Venom Market, By Reptile Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Snake
         1.1. Common Cobra
         1.2. Common Krait
         1.3. Russell Viper
         1.4. Others
        2. Scorpion
        3. Spider
        4. Others 

  • 9.   Anti-Venom Market, By Mode Of Action Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cytotoxic
        2. Neurotoxic
        3. Haemotoxic
        4. Cardiotoxic
        5. Myotoxic
        6. Others

  • 10.   North America Anti-Venom Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Anti-Venom Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Anti-Venom Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Anti-Venom Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Medtoxin Venom Laboratories
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Institute of Immunology
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Alomone Labs, Ltd.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Sigma Aldrich
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Wyeth Pharmaceuticals Limited
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Protherics PLC
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bharat Serums and Vaccines Limited
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Butantan Institute
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Haffkine Bio-Pharmaceutical Corporation Limited
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Micropaharm Limited
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients